Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 8/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5364718 | 1.00 | NR1H3 (0.59) | NR1H3MEN1KMT2AALOX15BCHE | |
| SCHEMBL4950622 | 0.94 | NR1H3 (0.53) | NR1H3 | |
| SCHEMBL5347613 | 0.88 | NR1H3 (0.64) | NR1H3MEN1KMT2AKDM4E | |
| SCHEMBL5347609 | 0.88 | NR1H3 (0.64) | NR1H3MEN1KMT2AKDM4E | |
| SCHEMBL9835890 | 0.86 | ALDH1A1 (0.56) | NR1H3KDM4E | |
| SCHEMBL5347615 | 0.82 | MAOB (0.52) | NR1H3MEN1KMT2A | |
| SCHEMBL5347623 | 0.82 | MAOB (0.52) | NR1H3MEN1KMT2A | |
| SCHEMBL5359397 | 0.82 | MAOB (0.52) | NR1H3MEN1KMT2A | |
| SCHEMBL5353930 | 0.81 | MAOB (0.59) | NR1H3MEN1KMT2A | |
| SCHEMBL11522447 | 0.79 | L3MBTL1 (0.52) | MEN1KMT2ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247748-B2 | Amide compounds and methods of using the same | SMITHKLINE CORPORATION (US) | 2007-07-24 | — | — | US | claimed |
| JP-2006514925-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1497270-A4 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | claimed |
| US-20050107444-A1 | Amide compounds and methods of using the same | GLAXOSMITHKLINE LLC | 2005-05-19 | — | — | US | claimed |
| EP-1497270-A1 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SmithKline Beecham Corporation (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2004043939-A1 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | claimed |
| US-7247748-B2 | Amide compounds and methods of using the same | SMITHKLINE CORPORATION (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1497270-A4 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050107444-A1 | Amide compounds and methods of using the same | GLAXOSMITHKLINE LLC | 2005-05-19 | — | — | US | disclosed |
| EP-1497270-A1 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SmithKline Beecham Corporation (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004043939-A1 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| US-5480910-A | 4-(2-(2-HYDROXY-2-PHENYLETHYLAMINO)ETHOXY)PHENYLACETIC ACID OR SALT IS ADMINISTERED FOR GASTROINTESTINAL DISORDERS | ZENECA LIMITED (GB) | 1996-01-02 | — | — | US | disclosed |
| US-5434184-A | B3-adrenoceptor agonist | ZENECA LIMITED (GB) | 1995-07-18 | — | — | US | disclosed |
| US-5393779-A | Anti-obesity, hypoglycemic, adrenergic blocking agents | ZENECA LIMITED (GB) | 1995-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107444-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | NR1H3 2/4885MEN1 4343/4885KMT2A 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.